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Background
Omalizumab is a recombinant humanized anti-IgE mono-
clonal antibody, indicated for add-on therapy for moder-
ate- to severe-persistent allergic (IgE-mediated) asthma.
Interim results at the 16 weeks time point of this 52 week
study have previously been presented. We present a sub-
group analysis looking at the efficacy of omalizumab at
16 weeks in relation to the serum IgE levels at baseline.
Methods
This open-label, multi-center, observational, prospective
study, recruited 72 patients with moderate-to-severe
persistent allergic asthma. Clinical efficacy was evaluated
on the basis of improvement in asthma exacerbations,
days missed at work/college, hospitalizations, ACQ 5,
ACT scores, and FEV1. Safety and tolerability were also
assessed. Qualitative and quantitative variables are ana-
lyzed using Chi-Square tests and paired t-tests, respec-
tively. All parameters are comparing results at week 16
of omalizumab treatment with those at baseline.
Results
Mean serum-IgE levels at baseline were 437.45 kIU L–1
(range 32-1599 kIU L–1). For analysis purposes patients
were categorized into three groups, according to their
baseline serum-IgE levels. Group 1 (n=31), comprised
patients with baseline serum-IgE levels of 32-250 kIU
L–1), and in group 2 (n=24) and 3 (n=17), patients with
baseline serum-IgE levels of 251-600 and >600 kIU L–1;
respectively. Mean (SD) age in three groups was 53.5
(9.6), 43.8 (15.3) and 60.5 (13.5) years; correspondingly.
In group 1, FEV1 levels improved by 0.27 liters (0.88 vs.
1.15, 95%CI ; p=0.000) and in group 2 and 3 by 0.67
liters (1.32 vs. 2.00, 95%CI ; p=0.001) and by 0.55 liters
(1.27 vs. 1.46, 95%CI ; p=0.002); respectively. Improvement
in FEV1 levels was more prominent amongst patients with
serum-IgE levels >600 kIU L–1. This change in FEV1
levels in 3 groups, was significantly different, as deter-
mined by one-way ANOVA (F (2,23)=7.959, p=0.002).
Conclusion
In these patients add-on therapy with omalizumab
improved lung function, quality of life and other clinical
measures. In this small sub group analysis, the improve-
ment was more marked in patients with a higher IgE
level at baseline.
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